South Korean biosimilars specialist Celltrion Healthcare (Kosdaq: 068270) has presented new Phase IV data for Truxima (rituximab-abbs) at the annual meeting of the European Hematology Association (EHA).
The multi-country post-approval study is the first to investigate the safety and effectiveness of Truxima in people with diffuse large B-cell lymphoma (DLBCL) in a real-world setting.
The data presented at EHA show that at 30-months post-index, 67% of those taking Truxima as a first-line option had not experienced disease progression, with 74% overall survival.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze